CRAVES FRED B 4
4 · MADRIGAL PHARMACEUTICALS, INC. · Filed Mar 14, 2025
Insider Transaction Report
Form 4
CRAVES FRED B
Director
Transactions
- Sale
Common Stock
2025-03-12$332.38/sh−2,382$791,726→ 351,076 total - Sale
Common Stock
2025-03-12$334.97/sh−200$66,994→ 350,076 total - Sale
Common Stock
2025-03-13$328.68/sh−400$131,472→ 351,118 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-03-12−1,728→ 7,742 totalExercise: $65.06Exp: 2025-06-16→ Common Stock (1,728 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-03-13−7,742→ 0 totalExercise: $65.06Exp: 2025-06-16→ Common Stock (7,742 underlying) - Exercise/Conversion
Common Stock
2025-03-12$65.06/sh+1,728$112,424→ 351,804 total - Exercise/Conversion
Common Stock
2025-03-12$111.06/sh+6,000$666,360→ 357,804 total - Sale
Common Stock
2025-03-12$330.54/sh−1,587$524,560→ 356,217 total - Sale
Common Stock
2025-03-12$331.36/sh−2,759$914,221→ 353,458 total - Sale
Common Stock
2025-03-12$333.66/sh−800$266,926→ 350,276 total - Exercise/Conversion
Common Stock
2025-03-13$65.06/sh+7,742$503,695→ 357,818 total - Sale
Common Stock
2025-03-13$322.45/sh−1,951$629,100→ 355,867 total - Sale
Common Stock
2025-03-13$323.47/sh−1,649$533,394→ 354,218 total - Sale
Common Stock
2025-03-13$324.69/sh−900$292,218→ 353,318 total - Sale
Common Stock
2025-03-13$325.63/sh−800$260,501→ 352,518 total - Sale
Common Stock
2025-03-13$327.63/sh−1,000$327,627→ 351,518 total - Sale
Common Stock
2025-03-13$329.86/sh−967$318,975→ 350,151 total - Sale
Common Stock
2025-03-13$330.23/sh−75$24,767→ 350,076 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-03-12−6,000→ 0 totalExercise: $111.06Exp: 2025-06-17→ Common Stock (6,000 underlying)
Holdings
- 1,261(indirect: See Footnotes)
Common Stock
- 21,000(indirect: See Footnotes)
Common Stock
- 11,210(indirect: See Footnote)
Common Stock
Footnotes (16)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $330.00 to $330.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $327.19 to $328.18, inclusive.
- [F11]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $328.20 to $329.165, inclusive.
- [F12]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $329.22 to $330.20, inclusive.
- [F13]Represents shares held indirectly by Dr. Craves through a grantor retained annuity trust.
- [F14]These securities are held by Bay City Capital LLC ("BCC"). Dr. Craves disclaims beneficial ownership of these securities held by BCC, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.
- [F15]Represents shares held indirectly by Dr. Craves through the Craves Family Foundation.
- [F16]The shares underlying this stock option are fully vested and exercisable.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $331.00 to $331.89, inclusive.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $332.01 to $332.88, inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $333.39 to $333.89, inclusive.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $334.95 to $334.99, inclusive.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $322.02 to $323.00, inclusive.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $323.02 to $323.97, inclusive.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $324.16 to $324.84, inclusive.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $325.34 to $325.955, inclusive.